A review finds GLP-1 receptor agonists improve coronary microvascular function by enhancing endothelial health, increasing nitric oxide, and reducing oxidative stress and inflammation in heart blood vessels.
Myocardial perfusion reserve improvedGLP-1 receptor agonists enhance coronary microvascular function through multiple mechanisms including improved endothelial health and increased nitric oxide
What the researchers found
The review summarizes evidence that GLP-1R activation improves coronary microvascular function through multiple mechanisms:
- Improved endothelial function in coronary microvasculature
- Increased nitric oxide bioavailability
- Attenuation of oxidative stress
- Reduced vascular inflammation
- Improved myocardial blood flow and myocardial perfusion reserve
- Enhanced coronary endothelial function, particularly in high-risk populations with T2D
- Benefits extend beyond glycemic control to direct cardiovascular effects
- Inconsistencies across studies due to variability in populations, designs, and imaging methods
Why it matters
Coronary microvascular dysfunction affects millions of people, especially those with diabetes, but has no specific approved treatment. If GLP-1 drugs can improve microvascular blood flow to the heart, this could explain part of their cardiovascular benefit and position them as targeted therapy for a currently undertreated condition.
How the study worked
This is a narrative review synthesizing preclinical and clinical evidence on GLP-1 receptor agonists' effects on coronary microvascular function. The review covers molecular mechanisms, animal model data, and clinical imaging studies of myocardial perfusion in patients treated with GLP-1 drugs.
What this study cannot tell us
As a narrative review, no original data is presented. The evidence base includes both preclinical and clinical studies of varying quality. Inconsistencies across studies make definitive conclusions difficult. Most clinical studies were relatively small, and imaging methodologies for assessing microvascular function vary. Large-scale trials specifically designed to test GLP-1 effects on coronary microcirculation are lacking.
How to read the evidence
This is a narrative review covering both preclinical and clinical evidence. While it provides a compelling mechanistic framework, the clinical evidence is limited to relatively small studies with inconsistent methodology.
When this study was published
Published in 2025, this review reflects the latest understanding of how GLP-1 drugs affect heart blood flow at the microvascular level.
The bigger picture
The cardiovascular benefits of GLP-1 drugs have been established in large outcome trials, but the mechanisms aren't fully understood. This review highlights microvascular improvement as a potentially important mechanism, complementing the known effects on atherosclerosis and blood pressure. Understanding these microvascular effects could lead to more targeted use of GLP-1 drugs in patients with specific cardiovascular conditions.
Questions still open
- Would GLP-1 drugs benefit patients with coronary microvascular dysfunction who don't have diabetes?
- Which GLP-1 receptor agonist is most effective at improving myocardial perfusion?
- Could myocardial perfusion imaging be used to identify which patients would benefit most from GLP-1 therapy?
Common questions
How do GLP-1 drugs help the heart's blood vessels?
What is coronary microvascular dysfunction?
Read the original research
GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes.
International journal of molecular sciences, 26(7)
Citation
Karakasis, Paschalis; Patoulias, Dimitrios; Theofilis, Panagiotis; Pamporis, Konstantinos; Sagris, Marios; Vlachakis, Panayotis K; Koufakis, Theocharis; Antoniadis, Antonios P; Fragakis, Nikolaos. (2025). GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes.. International journal of molecular sciences, 26(7). https://doi.org/10.3390/ijms26073050